Friday, 09 September 2022

COMPANY RESULTS

Civmec (CVL SP)

FY22: Results Above Expectations; Positive Outlook For Future Growth

Civmec's FY22 net profit of A\$51m (+47% yoy) beat our expectations by 13% due to robust revenue growth across most sectors and net margin expansion. Dividend also exceeded our expectations by 20%, with a full-year DPS of 3.0 A cents (+50% yoy), representing a dividend yield of 4.7%. Civmec remains positive on its future outlook given the strong tendering opportunities across all the sectors in which it operates. Maintain BUY with a 9% higher target price of S\$1.18.

FY22 RESULTS

Year to 31 Jun (A\$m)	FY22	FY21	yoy % chg
Revenue	809.3	674.2	20.0
EBITDA	94.5	73.8	28.1
EBITDA margin (%)	11.7%	10.9%	0.8 ppt
Net Profit	50.7	34.6	46.5
Net margin (%)	6.3%	5.1%	1.2 ppt

Source: Civmec, UOB Kay Hian

RESULTS

- Results above expectations from revenue growth across most sectors and margins expansion. Civmec's FY22 net profit of A\$51m (+47% yoy) was above our expectations by 13%. Revenue grew 20% yoy, with the infrastructure & defence segment growing 95% yoy and the resources segment growing 13% yoy. On the other hand, the energy segment, which forms around 4% of total revenue, fell 21% yoy. EBITDA margin expanded by 0.8ppt while net margin grew 1.2ppt, mainly due to better operating leverage and more favourable contract terms as most of Civmec's customers in the resources industry are making good profit.
- Strong tender activity indicates more contract wins. Tendering activity remains strong
 across all the sectors that Civmec operates in and it is focused on securing projects that will
 grow its workforce at a sustainable rate. Civmec remains positive about the pipeline and the
 opportunities to continually replenish its orderbook. Civmec is also increasingly focused on
 growing the proportion of revenue earned on long-term contracts.
- Progressing well on construction work of lithium plants in the green energy segment.
 Following the successful completion of the contract with Albemarle for construction work at their Kemerton lithium plant, work has now commenced on Civmec's contract to construct the Kwinana lithium refinery for Covalent. This represents the fourth lithium plant that Civmec has been involved in.
- Two new facilities under development to support growth. The previously announced facility in Port Hedland has achieved a significant milestone, with the recent settlement of the land purchase and gaining of development approval. The facility will be developed over the next 12 months. In addition, Civmec has acquired a 28,510 sqm piece of land in the region to establish a permanent facility. This facility will replace the leased facility Civmec currently occupies and allow it to expand its service offerings in the region.

KEY FINANCIALS

Year to 30 Jun (A\$m)	2021	2022	2023F	2024F	2025F
Net turnover	674	809	897	987	1,085
EBITDA	68	89	94	99	108
Operating profit	54	72	77	82	91
Net profit (rep./act.)	35	51	55	59	65
Net profit (adj.)	35	51	55	59	65
EPS (A\$ cent)	6.9	10.1	10.9	11.8	13.0
PE (x)	9.7	6.6	6.2	5.7	5.1
P/B(x)	1.1	0.9	8.0	0.7	0.7
EV/EBITDA (x)	5.4	4.2	3.9	3.7	3.4
Dividend yield (%)	3.0	4.5	4.8	5.2	6.0
Net margin (%)	5.2	6.3	6.1	6.0	6.0
Net debt/(cash) to equity (%)	4.0	8.9	0.8	(7.1)	(14.1)
Interest cover (x)	10.6	18.2	11.6	12.1	13.3
ROE (%)	12.5	15.3	14.0	13.8	13.8
Consensus net profit ()	-	-	52	57	-
UOBKH/Consensus (x)	-	-	1.04	1.05	-

Source: Civmec, Bloomberg, UOB Kay Hian

BUY

(Maintained)

Share Price	S\$0.64
Target Price	S\$1.18
Upside	+84.4%
(Previous TP	S\$1.08)

COMPANY DESCRIPTION

Civmec is an integrated, multi-disciplined construction and engineering services provider to the oil and gas, metals and minerals, infrastructure, and defence markets.

STOCK DATA

GICS sector	Industrials
Bloomberg ticker:	CVL SP
Shares issued (m):	502.4
Market cap (S\$\$m):	321.6
Market cap (US\$m):	229.8
3-mth avg daily t'over (US\$m):	0.1

Price Performance (%)

52-week high/low			S\$0.72	5/S\$0.565
1mth	3mth	6mth	1yr	YTD
4.9	(8.0)	2.4	(3.8)	(3.8)
Major S	hareholder	's		%
James Fir	nbarr Fitzgera	ald		19.5
Patrick John Tallon				19.5
FY23 NA	V/Share (A\$)			81.60
FY23 Net Debt/Share (A\$)				0.01

PRICE CHART



Source: Bloomberg

ANALYST(S)

John Cheong

+65 6590 6623

johncheong@uobkayhian.com



Friday, 09 September 2022

STOCK IMPACT

- Positive industry outlook for the resources and energy segment. Energy activity is expected to grow substantially over the next few years, peaking in FY24. Activity will be supported by major projects such as Gorgon Stage 2 (Western Australia), Pluto Stage 2, Scarborough Gas Field, the Surat Gas Project and the Barossa gas field. The hydrogen industry is gaining traction in Australia, and Civmec expects more projects to be announced over the forecast horizon. These include the Haber Project, Woodside's H2 Perth in Kwinana and Port Pirie Green Hydrogen Project (Southern Australia).
- Well-positioned to tap on emerging opportunities in the clean and new energy segments. With an increasing focus on emissions reductions worldwide, Australia is beginning to see increased activity with announcements for development of plants associated with supply of battery minerals, rare earths, hydrogen and ammonia plants. Australia's CSIRO (The Commonwealth Scientific and Industrial Research Organisation) has reported that in Australia and New Zealand, there are 60 hydrogen projects in various stages of development. The skills and experience Civmec has gained since inception puts it in a strong position to secure contracts for the manufacture of components and construction of these plants in the future.



• We raise our FY23/24 earnings forecasts by 16%/12%, after raising our revenue estimates by 4%/4% and gross margin estimate by around 0.2ppt to 11.5%/11.7% to reflect more contract wins and better margins that Civmec should enjoy given the more favourable commodity prices which will benefit the majority of its customers.

VALUATION/RECOMMENDATION

• Maintain BUY with a 9% higher target price of \$\$1.18, pegged to 12x FY23F PE (1SD below five-year mean). We think the current valuation of 6x FY23F PE is attractive, given its strong growth profile of 10% three-year EPS CAGR for FY22-25 and huge orderbook, especially in the defence sector which has a long tenure and high barriers to entry. Civmec's peers are trading at an average of 15x FY22F PE.

SHARE PRICE CATALYST


- Earnings surprise due to higher-than-expected contract wins and margin.
- Better-than-expected dividend.
- Takeover offer by strategic shareholder given the high entry barrier of defence business.

HUGE ADDRESSABLE MARKET FOR CIVMEC'S KEY SEGMENTS



Source: BIS Oxford Fconomics, Civmed

HUGE ENERGY CAPEX TO BENEFIT CIVMEC



Source: BIS Oxford Economics, Civmed



Friday, 09 September 2022

PROFIT & LOSS					BALANCE SHEET				
Year to 30 Jun (A\$m)	2022	2023F	2024F	2025F	Year to 30 Jun (A\$m)	2022	2023F	2024F	2025F
Net turnover	809.3	897.0	987.3	1,085.0	Fixed assets	448.1	447.1	446.1	445.1
EBITDA	88.5	94.2	98.6	108.3	Other LT assets	18.2	18.2	18.2	18.2
Deprec. & amort.	16.6	17.0	17.0	17.0	Cash/ST investment	40.8	70.7	106.1	144.3
EBIT	71.9	77.2	81.6	91.3	Other current assets	218.5	244.0	268.4	294.8
Total other non-operating income	2.9	3.0	3.0	1.0	Total assets	725.7	780.0	838.8	902.4
Associate contributions	0.0	0.0	0.0	0.0	ST debt	28.0	28.0	28.0	28.0
Net interest income/(expense)	(4.9)	(8.1)	(8.1)	(8.1)	Other current liabilities	180.7	196.4	213.2	231.4
Pre-tax profit	70.0	72.0	76.5	84.2	LT debt	46.0	46.0	46.0	46.0
Tax	(19.2)	(17.3)	(17.0)	(18.7)	Other LT liabilities	99.9	99.9	99.9	99.9
Minorities	0.0	(0.1)	(0.1)	(0.1)	Shareholders' equity	371.4	410.0	451.9	497.2
Net profit	50.8	54.7	59.5	65.4	Minority interest	(0.3)	(0.2)	(0.2)	(0.1)
Net profit (adj.)	50.8	54.7	59.5	65.4	Total liabilities & equity	725.7	780.0	838.8	902.4
CASH FLOW					KEY METRICS				
Year to 30 Jun (A\$m)	2022	2023F	2024F	2025F	Year to 30 Jun (A\$m)	2022	2023F	2024F	2025F
Operating	1.8	61.9	69.0	74.3	Profitability				
Pre-tax profit	70.0	72.0	76.5	84.2	EBITDA margin	10.9	10.5	10.0	10.0
Tax	(27.8)	(17.3)	(17.0)	(18.7)	Pre-tax margin	8.6	8.0	7.7	7.8
Deprec. & amort.	16.6	17.0	17.0	17.0	Net margin	6.3	6.1	6.0	6.0
Associates	0.0	0.0	0.0	0.0	ROA	7.5	7.3	7.3	7.5
Working capital changes	(56.7)	(9.8)	(7.6)	(8.2)	ROE	15.3	14.0	13.8	13.8
Non-cash items	(0.2)	0.0	0.0	0.0					
Other operating cashflows	(0.2)	0.0	0.0	0.0	Growth				
Investing	(6.5)	(16.0)	(16.0)	(16.0)	Turnover	20.0	10.8	10.1	9.9
Capex (growth)	(6.9)	(16.0)	(16.0)	(16.0)	EBITDA	29.5	6.4	4.7	9.8
Investments	0.0	0.0	0.0	0.0	Pre-tax profit	39.4	2.9	6.2	10.0
Proceeds from sale of assets	0.3	0.0	0.0	0.0	Net profit	46.0	7.7	8.7	10.0
Others	0.1	0.0	0.0	0.0	Net profit (adj.)	46.0	7.7	8.7	10.0
Financing	(2.6)	(16.1)	(17.6)	(20.1)	EPS	45.7	7.7	8.7	10.0
Dividend payments	(10.0)	(16.1)	(17.6)	(20.1)					
Proceeds from borrowings	154.4	0.0	0.0	0.0	Leverage				
Loan repayment	(139.5)	0.0	0.0	0.0	Debt to total capital	16.6	15.3	14.1	13.0
Others/interest paid	(7.5)	0.0	0.0	0.0	Debt to equity	19.9	18.0	16.4	14.9
Net cash inflow (outflow)	(7.3)	29.9	35.4	38.2	Net debt/(cash) to equity	8.9	0.8	(7.1)	(14.1)
Beginning cash & cash equivalent	48.2	40.8	70.7	106.1	Interest cover (x)	18.2	11.6	12.1	13.3
Changes due to forex impact	(0.0)	0.0	0.0	0.0					
Shanges add to for on impact	40.8	70.7	106.1	0.0					



Friday, 09 September 2022

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.



Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

ollowing table.	
General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning
Kingdom	of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United	,
	the UK is intended only for institutional clients.
United	the UK is intended only for institutional clients. This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S.

Copyright 2022, UOB Kay Hian Pte Ltd. All rights reserved.

http://research.uobkayhian.com

RCB Regn. No. 197000447W